ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase
4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase
FY 2023 Total Revenue Expected to Exceed $210 Million
Related news for (ADMA)
- ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
- ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
- ADMA Biologics Statement on Tariffs
- ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update